Panel Schedule « Solebury Trout KOL Day

Event Panel Schedule

Fri, 15 Nov 2019

	TBA
	Clinical Insights of New Rapidly Acting, NMDA-based Antidepressants Robert Besthof , CMO / NeuroRx Developing first Glx targeted antidepressant to address suicidality in bipolar depression. Lead candidate, NRX-101 is in Ph 2b/3 development, (Breakthrough Designation, SPA and Fast Track Designation by FDA) for Severe Bipolar Depression in pts w… Developing first Glx targeted antidepressant to address suicidality in bipolar depression. Lead candidate, NRX-101 is in Ph 2b/3 development, (Breakthrough Designation, SPA and Fast Track Designation by FDA) for Severe Bipolar Depression in pts w Acute Suicidal Ideation and Behavior. Reported Ph 2 efficacy and safety data for NRX-011 in Dec 18, suggesting potential for NRX-101 in maintaining remission from several bipolar depression with acute suicidal ideation following an initial stabilization with ketamine. Co is also leading Relief Therapeutics’ Ph 2 trial of Aviptadil to treat COVID-19 induced ARDS in the US.
	NK cell expansion and proliferation with PM21 particles: adjunctive therapy for hematopoietic stem cell transplantation and potential treatment for both liquid and solid tumors Arthur Lahr , CEO / Kiadis Pharma N.V. Arthur Lahr is Chief Executive Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Chief Strategy Officer and member of the Management Committee at Crucell from 2001 until its acquisition by Johnson & Johnson in 2011. Before that he… Arthur Lahr is Chief Executive Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Chief Strategy Officer and member of the Management Committee at Crucell from 2001 until its acquisition by Johnson & Johnson in 2011. Before that he was consultant at McKinsey & Company and engineer at Unilever. At present, Mr. Lahr also serves as a member of the supervisory board of Sanquin, the Dutch national plasma and blood product supplier. Mr. Lahr holds a Masters degree in Applied Physics from the University of Delft, The Netherlands, and an MBA from INSEAD, France.
	Three clinical-stage cell therapy programs in dry age-related macular degeneration, spinal cord injury, and oncology Brian Culley , CEO / Lineage Cell Therapeutics Mr. Culley joined BioTime as CEO in September 2018. Prior to joining BioTime, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management… Mr. Culley joined BioTime as CEO in September 2018. Prior to joining BioTime, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (“Mast”), from February 2010, and was also a member of its Board of Directors from December 2011, until Mast’s merger with Savara, Inc. in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.
	SCLC: Recent approvals in first and third line could be joined with Lurbinectedin in 2nd line Pascal Besman , Chief Operating Officer (PharmaMar U.S.) / PharmaMar SA Prior to joining JMP, Pascal was a partner and institutional salesperson at Maxim and also ThinkEquity for three years. He previously served as a senior vice president at UBS and has held equity sales positions at Bear Stearns, Lehman Brothers and… Prior to joining JMP, Pascal was a partner and institutional salesperson at Maxim and also ThinkEquity for three years. He previously served as a senior vice president at UBS and has held equity sales positions at Bear Stearns, Lehman Brothers and Merrill Lynch, both in the U.S. and in London. Pascal holds a B.Sc. from the London School of Economics.
	Oncolytic adenovirus armed w immune stimulating transgene targeting basket of I-O indications Torbjørn Furuseth , Chief Financial Officer / Targovax An experienced executive with a broad background within life science. He joins from the clinical stage immune-oncology company Lytix Biopharma, where he has served as CFO and conducted several financing rounds. Prior to this, he was EVP Innovation at… An experienced executive with a broad background within life science. He joins from the clinical stage immune-oncology company Lytix Biopharma, where he has served as CFO and conducted several financing rounds. Prior to this, he was EVP Innovation at Aker BioMarine, where he established and led the innovation department. Torbjørn also brings six years’ experience as a management consultant at McKinsey & Company, where he served several pharma and healthcare clients. Torbjørn is a Medical Doctor from Norwegian University of Science and Technology (NTNU).
	E-CEL® (Engineered Endothelial Cell) Therapy and Vascular Niche Biology Paul Finnegan , CEO / Angiocrine Bioscience Dr. Finnegan is Chief Executive Officer of Angiocrine Bioscience. He has more than 20 years of life science management experience in the biotechnology, pharmaceutical, and healthcare industries

1573840800 - 1573845300

Clinical Insights of New Rapidly Acting, NMDA-based Antidepressants

1573846200 - 1573850700

NK cell expansion and proliferation with PM21 particles: adjunctive therapy for hematopoietic stem cell transplantation and potential treatment for both liquid and solid tumors

1573851600 - 1573856100

Three clinical-stage cell therapy programs in dry age-related macular degeneration, spinal cord injury, and oncology

1573857000 - 1573861500

SCLC: Recent approvals in first and third line could be joined with Lurbinectedin in 2nd line

1573862400 - 1573866900

Oncolytic adenovirus armed w immune stimulating transgene targeting basket of I-O indications

1573867800 - 1573868700

E-CEL® (Engineered Endothelial Cell) Therapy and Vascular Niche Biology

Export to Excel

Event Panel Schedule

Clin­i­cal In­sights of New Rapid­ly Act­ing, NM­DA-based An­tide­pres­sants

NK cell ex­pan­sion and pro­lif­er­a­tion with PM21 par­ti­cles: ad­junc­tive ther­a­py for he­ma­topoi­et­ic stem cell tran­s­plan­ta­tion and po­ten­tial treat­ment for both liquid and solid tu­mors

Three clin­i­cal-stage cell ther­a­py pro­grams in dry age-re­lat­ed mac­u­lar de­gen­er­a­tion, spi­nal cord in­jury, and on­col­o­gy

SCLC: Re­cent ap­pro­vals in first and third line could be joined with Lur­binecte­din in 2nd line